Citigroup
CYCN icon

Citigroup’s Cyclerion Therapeutics CYCN Stock Holding History

Citigroup’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-89
Closed -$137 – 5835
2026
Q1 		$137 Sell
89
-8,115
-99% -$11.5K ﹤0.01% 5596
2025
Q4 		$10.4K Buy
+8,204
New +$14.6K ﹤0.01% 5041
2021
Q2 		– Sell
-73
Closed -$4K – 6168
2021
Q1 		$4K Sell
73
-141
-66% -$10.6K ﹤0.01% 5934
2020
Q4 		$13K Buy
214
+161
+304% +$11K ﹤0.01% 6856
2020
Q3 		$6K Sell
53
-106
-67% -$12.1K ﹤0.01% 6890
2020
Q2 		$19K Sell
159
-179
-53% -$15K ﹤0.01% 6646
2020
Q1 		$18K Sell
338
-87
-20% -$6.21K ﹤0.01% 6749
2019
Q4 		$23K Buy
425
+137
+48% +$12.8K ﹤0.01% 6865
2019
Q3 		$69K Sell
288
-24
-8% -$5.18K ﹤0.01% 5919
2019
Q2 		$71K Buy
+312
New +$88.3K ﹤0.01% 6162

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Citigroup's CYCN Position: Q2 2026 in Review

Citigroup sold out of Cyclerion Therapeutics (CYCN) in Q2 2026, closing a stake of 89 shares — an estimated $137 sold.

Citigroup first reported a position in CYCN in Q2 2019 and held it in 10 quarters. The position peaked at $71K in Q2 2019. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Citigroup reported no remaining Cyclerion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citigroup sold 89 Cyclerion Therapeutics shares in Q2 2026, an estimated $137.
  • Citigroup first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 10 quarters.
  • Citigroup's Cyclerion Therapeutics position peaked at $71K in Q2 2019.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.